

## Highlight

### U.S. stocks may hit a bumper.

The S&P 500 did finish strong in 2023 with the index gaining more than 4% for the month of December. Investor concerns over rising interest rates, slowing economic growth and high inflation subsided in 2023, and investor enthusiasm for artificial intelligence technology fueled one of the Nasdaq Composite's best annual total returns since 2009. Technology stocks, growth stocks and cryptocurrencies were top performers in 2023 as appetite for risk assets returned to the market.

Heading into 2024, inflation seems to be trending steadily lower. However, some analysts and economists are concerned the final leg of the Federal Reserve's battle with inflation will be more difficult than expected, and a U.S. recession could still be looming.



### Bitcoin

Bitcoin has been doing well. We think the recent pause in rate hike might lend further strength to its upward momentum.



### China

The Chinese market did not perform well in 2023. We expect Chinese stocks to recover as Chinese government is expected to increase fiscal stimulus to boost economic growth.



### Energy Prices

Oil prices are beginning to trend higher due to geopolitical tension in the Middle East. We think oil price will hover around the current level.

## Market Update

Index	Last Price	2022	2023	YTD%	PE_Ratio
Nasdaq	14,592.21	-33%	43%	39%	38.31
S&P500	4,704.81	-19%	24%	23%	22.63
STOXX Europe 600 Price Index EUR	474.40	-13%	13%	12%	13.60
China	2,941.40	-15%	-4%	-5%	13.65
Hong kong	16,566.05	-15%	-14%	-16%	8.73
India	71,356.60	4%	19%	17%	24.91
Singapore	3,178.90	4%	0%	-2%	11.20
THAI	1,425.50	1%	-15%	-15%	19.61
Vietnam	1,147.94	-33%	12%	14%	15.22
Malaysia	1,469.23	-5%	-3%	-2%	15.15
Indonesia	3,683.74	11%	3%	3%	15.14

Source : Bloomberg as of 03/01/2024

### Investment Thesis

We still like U.S. equities due to their global and international business presence. Some U.S. equities are currently trading at compelling valuation. In addition to U.S. equities, we like technology and life science sectors due to their future potential growth and more importantly they are trading at very compelling price.

Disclaimer

This analysis is for informational purposes only. This analysis is not a guide or suggesting purchasing or selling any securities or any financial instrument. The company can't be liable for any damages arising from or related to its use in all cases. However, The Company can't certify the accuracy and completeness of such information. Investors should consult with your investment advisor before investing.



## Fund Outlook



Positive



Negative

Fund	Previous As of December 2023	New As of January 2024
SCB US EQUITY FUND (SCBS&P500)	▲	▲
TMB Eastspring Asia Active Equity (TMBAGLF)	▲	▲
Thanachart Global Energy (T-GlobalEnergy)	▲	▲
SCB Innovation (SCBINNO)	▲	▲
TMB Eastspring Genomic Revolution (TMB-ES-GENOME)	▲	▲

**Disclaimer**

This analysis is for informational purposes only. This analysis is not a guide or suggesting purchasing or selling any securities or any financial instrument. The company can't be liable for any damages arising from or related to its use in all cases. However, The Company can't certify the accuracy and completeness of such information. Investors should consult with your investment advisor before investing.



## Investment Theme



### Long Term

#### USA

- SCB US EQUITY FUND (SCBS&P500)** ★★★★★ Morningstar Rating 4 star  
As of 30 November 2023
  - SCBS&P500 has an investment policy focus on investing in one foreign mutual fund (Feeder Fund), namely: iShares Core S&P 500 ETF. (Master Fund)
  - The fund has been downgraded from a 5-star to 4-star by MorningStar.
  - The fund mainly invests in companies operating around the world and not only the United States. In addition, the fund invests in a large company and a strong international brandname such as Apple, Mcdonald's, Google and Microsoft, etc. If the United States is an economic recession, the fund is less affected.
  - For the past month, the iShares Core S&P 500 ETF performed well because investors believe that U.S. Fed will not hike interest rate.
  - Risk Level : 6 (High Risk)
- Low 

1	2	3	4	5	6	7	8
---	---	---	---	---	---	---	---

 High

#### ASIA EX JAPAN

- TMB Eastspring Asia Active Equity (TMBAGLF)** ★★★★★ Morningstar Rating 3 star  
As of 30 November 2023
  - TMBAGLF has an investment policy focus on investing in one foreign mutual fund (Feeder Fund), namely: Schroder International Selection Fund - Emerging Asia. (Master Fund)
  - The fund has a 3-star MorningStar Rating. We view this as a long-term investment with much upside potential.
  - For the past month, the fund performed well because investors believe that U.S. Fed will not hike interest rate.
  - Risk Level : 6 (High Risk)
- Low 

1	2	3	4	5	6	7	8
---	---	---	---	---	---	---	---

 High



### Short Term

#### Energy

- Thanachart Global Energy (T-GlobalEnergy)** ★★★★★ Morningstar Rating no star  
As of 30 November 2023
  - T-GlobalEnergy has a policy to diversify investment in foreign mutual funds and/or foreign ETFs in the energy-related technology sector both in the upstream and downstream industries, exploration, development and distribution of energy.
  - Although T-GlobalEnergy is not rated by Morningstar, however, the fund is still the AIAM's top pick.
  - We still maintain a positive view on energy stocks although the global economy is slowing down. However, oil prices have also been boosted by the Russian-Ukrainian conflict and relaxation of COVID-19 lockdown measures. In addition, OPEC signals that they may cut oil supply.
  - Risk Level : 7 (High Risk)
- Low 

1	2	3	4	5	6	7	8
---	---	---	---	---	---	---	---

 High

Disclaimer

This analysis is for informational purposes only. This analysis is not a guide or suggesting purchasing or selling any securities or any financial instrument. The company can't be liable for any damages arising from or related to its use in all cases. However, The Company can't certify the accuracy and completeness of such information. Investors should consult with your investment advisor before investing.



## Investment Theme



### Turnaround

#### ARKK

- **SCB Innovation (SCBINNO)** ★★★★★ Morningstar Rating no star As of 30 November 2023
- SCBINNO has an investment policy focus on investing in one foreign mutual fund (Feeder Fund), namely: ARK INNOVATION ETF (ARKK) (Master Fund) and ETF has Active Management.
- Although SCBINNO is not rated by Morningstar, however, the fund is still the AIAM's top pick.
- ARKK is a popular fund with Cathie Wood as the fund manager who has been able to multiply investors' profits over the past year. Although the fund has decreased by about 70%, however, the fund still has good fundamental because of investing in new technology and innovation stocks. AIAM seen as an opportunity to invest because AIAM believed that this fund will be able to recover.
- For the past month, the ARK INNOVATION ETF (ARKK) performed well because investors believe that U.S. Fed will not hike interest rate. The fund has huge upside potential.
- The SCBINNO fund has been operated for 1 year, however, the ARK INNOVATION ETF (ARKK) has been operated for more than 5 years.
- Risk Level : 6 (High Risk)

Low 

1	2	3	4	5	6	7	8
---	---	---	---	---	---	---	---

 High

#### ARKG

- **TMB Eastspring Genomic Revolution (TMB-ES-GENOME)** ★★★★★ Morningstar Rating no star As of 30 November 2023
- TMB-ES-GENOME has an investment policy focus on investing in one foreign mutual fund (Feeder Fund), namely: ARK Genomic Revolution ETF (ARKG)(Master Fund) and ETF has Active Management.
- Although TMB-ES-GENOME is not rated by Morningstar, however, the fund is still the AIAM's top pick.
- ARKG is a very popular fund that has multiple yielded over the past year because technology stocks have grown exponentially. Although the fund is currently decrease about 60% from the previous year, the company has confidence in Cathie Wood, a fund manager who has the ability to manage the fund and pick stocks that are expected to grow in the future. Including climate change leading to the emergence of new diseases. It is a positive factor to invest in the medical innovation sector in the future.
- For the past month, the ARK Genomic Revolution ETF (ARKG) performed well because investors believe that U.S. Fed will not hike interest rate. The fund has huge upside potential.
- The TMB-ES-GENOME fund has been operated for 1 year, however, the ARK Genomic Revolution ETF (ARKG) has been operated for more than 5 years.
- Risk Level : 7 (High Risk)

Low 

1	2	3	4	5	6	7	8
---	---	---	---	---	---	---	---

 High

Source : Bloomberg ,SCBAM , Eastspring Investments,abrdn,one asset management

**Disclaimer**

This analysis is for informational purposes only. This analysis is not a guide or suggesting purchasing or selling any securities or any financial instrument. The company can't be liable for any damages arising from or related to its use in all cases. However, The Company can't certify the accuracy and completeness of such information. Investors should consult with your investment advisor before investing.

